Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Homepage
  2. Equities
  3. China
  4. Shenzhen Stock Exchange
  5. Pharmaron Beijing Co., Ltd.
  6. News
  7. Summary
    300759   CNE100003JW4

PHARMARON BEIJING CO., LTD.

(300759)
  Report
End-of-day quote Shenzhen Stock Exchange  -  2022-12-01
65.01 CNY   -2.43%
10/31Global markets live: IAG, Credit Suisse, Foxconn, General Motors, Blackstone...
MS
10/28Nomura Adjusts Pharmaron Beijing's Price Target to 90.01 Yuan From 99.95 Yuan, Keeps at Buy
MT
10/28Nomura Adjusts Pharmaron Beijing's Price Target to HK$62.19 From HK$91.89, Keeps at Buy
MT
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Pharmaron Beijing Co., Ltd. Announces Board Changes

08/29/2022 | 10:53am EST

The Board of Pharmaron Beijing Co., Ltd. hereby announced that Mr. Dai Lixin ("Mr. Dai") and Ms. Chen Guoqin ("Ms. Chen") will cease to be the independent non-executive Director of the Company, with effect from the conclusion of the extraordinary general meeting of the Company to be held on September 23, 2022 (the "EGM"), in light of the upcoming expirations of their respective six-year consecutive terms of offices, as required according to the Rules for Independent Directors of Listed Companies of the China Securities Regulatory Commission. Immediately following Mr. Dai's and Ms. Chen's respective cessations of office, Mr. Dai will cease to be a member of the strategy committee of the Company, and Ms. Chen will also
cease to be the chairwoman of the nomination committee and the remuneration and appraisal committee of the Company, and a member of the audit committee of the Company.


ę S&P Capital IQ 2022
All news about PHARMARON BEIJING CO., LTD.
10/31Global markets live: IAG, Credit Suisse, Foxconn, General Motors, Bl..
MS
10/28Nomura Adjusts Pharmaron Beijing's Price Target to 90.01 Yuan From 99.95 Yuan, Keeps at..
MT
10/28Nomura Adjusts Pharmaron Beijing's Price Target to HK$62.19 From HK$91.89, Keeps at Buy
MT
10/27Pharmaron Beijing's Q3 Net Profit Falls 21%
MT
10/27Pharmaron Beijing Co., Ltd. Reports Earnings Results for the Nine Months Ended Septembe..
CI
10/27Pharmaron Beijing Co., Ltd. entered into equity transfer agreement to acquire 21.6874% ..
CI
09/27Pharmaron Posts Yearly Increase in H1 Profit
MT
09/23Pharmaron Beijing Co., Ltd. Announces Board Appointments
CI
09/12Wuxi Biologics, Peers Slump After Biden Signs Order to Boost U.S. Biotech Industry
DJ
08/29Pharmaron Beijing Co., Ltd. Announces Board Changes
CI
More news
Analyst Recommendations on PHARMARON BEIJING CO., LTD.
More recommendations
Financials
Sales 2022 10 291 M 1 466 M 1 466 M
Net income 2022 1 652 M 235 M 235 M
Net Debt 2022 1 783 M 254 M 254 M
P/E ratio 2022 43,6x
Yield 2022 0,47%
Capitalization 72 575 M 10 339 M 10 339 M
EV / Sales 2022 7,23x
EV / Sales 2023 5,56x
Nbr of Employees -
Free-Float 34,9%
Chart PHARMARON BEIJING CO., LTD.
Duration : Period :
Pharmaron Beijing Co., Ltd. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends PHARMARON BEIJING CO., LTD.
Short TermMid-TermLong Term
TrendsBullishNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 12
Last Close Price 65,01 CNY
Average target price 84,11 CNY
Spread / Average Target 29,4%
EPS Revisions
Managers and Directors
Bo Liang Lou Chairman & Chief Executive Officer
Shing Chung Li Chief Financial Officer & Board Secretary
Ke Xin Yang Chairman-Supervisory Board & Vice President
Hua Yang Chief Scientific Officer
Xiao Qiang Lou Chief Operating Officer & Executive Director
Sector and Competitors
1st jan.Capi. (M$)
PHARMARON BEIJING CO., LTD.-30.97%10 339
MODERNA, INC.-28.20%70 055
IQVIA HOLDINGS INC.-22.83%40 441
LONZA GROUP AG-33.82%39 802
ALNYLAM PHARMACEUTICALS, INC.38.22%28 838
SEAGEN INC.-20.82%22 727